Associated Papers
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.
Borgeaud M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2024
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report.
Wu L et al.
Annals of Translational Medicine, 2022
Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: A study of 600 cases from a single center.
Musayeva M et al.
Turk Gogus Kalp Damar Cerrahisi Dergisi, 2020
Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic.
Freitas HC et al.
Frontiers in Oncology, 2020
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A et al.
International Journal of Molecular Sciences, 2019
DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression.
Mäki-Nevala S et al.
Ebiomedicine, 2019
Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.
Dallol A et al.
Journal of Translational Medicine, 2016
Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.
Kaderbhai CG et al.
Oncotarget, 2016
Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer.
Vu HA et al.
Asia-pacific Journal of Clinical Oncology, 2016
Twenty-One Novel EGFR Kinase Domain variants in Patients with Nonsmall Cell Lung Cancer.
Hasenahuer MA et al.
Annals of Human Genetics, 2015
The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer.
Karachaliou N et al.
Expert Review of Respiratory Medicine, 2015
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
Siroy AE et al.
The Journal of Investigative Dermatology, 2015
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
Yang CH
Lung Cancer (amsterdam, Netherlands), 2008
Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.
Hsieh MH et al.
Lung Cancer (amsterdam, Netherlands), 2006